European Countries Focus Horizon Scanning On Alzheimer’s Disease
BeNeLuxA Pre-Empts Access Challenges For Alzheimer's Disease
Working out what’s on the horizon in terms of potential new treatments for Alzheimer’s disease should help countries prepare for the challenges that will be involved when it comes to determining patient access.
You may also be interested in...
Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.
A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.